CA2629336A1 - [4-(benzo[b]thiophen-2-yl)pyrimidin-2yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases - Google Patents

[4-(benzo[b]thiophen-2-yl)pyrimidin-2yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases Download PDF

Info

Publication number
CA2629336A1
CA2629336A1 CA002629336A CA2629336A CA2629336A1 CA 2629336 A1 CA2629336 A1 CA 2629336A1 CA 002629336 A CA002629336 A CA 002629336A CA 2629336 A CA2629336 A CA 2629336A CA 2629336 A1 CA2629336 A1 CA 2629336A1
Authority
CA
Canada
Prior art keywords
benzo
carboxylic acid
pyrimidin
mmol
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002629336A
Other languages
English (en)
French (fr)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q. May Wang
Bo Zhang
Michael Enrico Richett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2629336A1 publication Critical patent/CA2629336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002629336A 2005-11-18 2006-11-15 [4-(benzo[b]thiophen-2-yl)pyrimidin-2yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases Abandoned CA2629336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
US60/738,097 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (1)

Publication Number Publication Date
CA2629336A1 true CA2629336A1 (en) 2007-08-16

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002629336A Abandoned CA2629336A1 (en) 2005-11-18 2006-11-15 [4-(benzo[b]thiophen-2-yl)pyrimidin-2yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases

Country Status (27)

Country Link
US (1) US7547691B2 (enExample)
EP (1) EP1989200B1 (enExample)
JP (1) JP2009516697A (enExample)
KR (1) KR100990771B1 (enExample)
CN (1) CN101309918B (enExample)
AR (1) AR057911A1 (enExample)
AT (1) ATE437873T1 (enExample)
AU (1) AU2006337626B2 (enExample)
BR (1) BRPI0618245A2 (enExample)
CA (1) CA2629336A1 (enExample)
CR (1) CR9947A (enExample)
DE (1) DE602006008187D1 (enExample)
DK (1) DK1989200T3 (enExample)
EA (1) EA014426B1 (enExample)
EC (1) ECSP088456A (enExample)
ES (1) ES2329085T3 (enExample)
IL (1) IL190489A0 (enExample)
MA (1) MA30053B1 (enExample)
NO (1) NO20082594L (enExample)
PE (1) PE20070833A1 (enExample)
PL (1) PL1989200T3 (enExample)
PT (1) PT1989200E (enExample)
SI (1) SI1989200T1 (enExample)
TN (1) TNSN08227A1 (enExample)
TW (1) TW200800201A (enExample)
WO (1) WO2007092095A2 (enExample)
ZA (1) ZA200803940B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2007752T3 (pl) 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
WO2008011560A2 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
WO2008076705A1 (en) * 2006-12-21 2008-06-26 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
JP5166441B2 (ja) 2006-12-21 2013-03-21 イーライ リリー アンド カンパニー 癌治療用イミダゾリジノニルアミノピリミジン化合物
US8063035B2 (en) 2007-05-16 2011-11-22 Eli Lilly And Company Triazolyl aminopyrimidine compounds
US8114872B2 (en) 2007-05-16 2012-02-14 Eli Lilly And Company Triazolyl aminopyrimidine compounds
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
PL2310012T3 (pl) 2008-06-30 2015-08-31 Janssen Pharmaceutica Nv Sposób wytwarzania podstawionych pochodnych pirymidyny
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
MY159995A (en) 2010-04-27 2017-02-15 Hutchison Medipharma Ltd Pyrimidinyl indole compounds
JP2014512364A (ja) 2011-04-07 2014-05-22 コーネル ユニバーシティー 水溶液中で二量体化できる単量体、およびその使用法
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
CA3132120C (en) 2012-02-08 2023-10-24 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
US9796699B2 (en) 2015-11-03 2017-10-24 Janssen Pharmaceutica Nv Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
EA201990399A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения, композиции и их применение
ES2996835T3 (en) 2016-07-29 2025-02-13 Sumitomo Pharma America Inc Compounds and compositions and uses thereof
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体kras、hrasまたはnrasの調節因子としてのキナゾリン誘導体
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
WO2020028706A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020186165A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2006066172A1 (en) 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use

Also Published As

Publication number Publication date
NO20082594L (no) 2008-06-10
SI1989200T1 (sl) 2009-12-31
ATE437873T1 (de) 2009-08-15
DK1989200T3 (da) 2009-11-09
KR20080059451A (ko) 2008-06-27
WO2007092095A2 (en) 2007-08-16
WO2007092095A3 (en) 2007-11-08
EA014426B1 (ru) 2010-12-30
EA200801362A1 (ru) 2009-02-27
IL190489A0 (en) 2008-11-03
MA30053B1 (fr) 2008-12-01
EP1989200A2 (en) 2008-11-12
CN101309918B (zh) 2010-12-29
AR057911A1 (es) 2007-12-26
AU2006337626B2 (en) 2012-03-22
AU2006337626A1 (en) 2007-08-16
AU2006337626A8 (en) 2008-06-19
ECSP088456A (es) 2008-06-30
KR100990771B1 (ko) 2010-10-29
ES2329085T3 (es) 2009-11-20
TW200800201A (en) 2008-01-01
PT1989200E (pt) 2009-10-12
PE20070833A1 (es) 2007-08-27
PL1989200T3 (pl) 2009-12-31
CR9947A (es) 2008-11-28
US7547691B2 (en) 2009-06-16
JP2009516697A (ja) 2009-04-23
BRPI0618245A2 (pt) 2011-08-23
DE602006008187D1 (de) 2009-09-10
EP1989200B1 (en) 2009-07-29
US20080306082A1 (en) 2008-12-11
CN101309918A (zh) 2008-11-19
ZA200803940B (en) 2009-09-30
TNSN08227A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
AU2006337626B2 (en) [4-(benzo [b] thiophen-2-yl) pyrimidin-2yl] -amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases.
EP1686999B1 (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP2044051B1 (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
US20090233928A1 (en) Imidazolo-5-yl-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
CA2406634A1 (en) Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor
WO2002051806A1 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
BRPI0618179A2 (pt) inibidores de biaril meta pirimidina de cinases
KR20140103996A (ko) Lrrk2 조절제로서 아미노피리미딘 유도체
AU2007242594A1 (en) Pyrimidine derivatives as PI3K inhibitors
CN102892761A (zh) 4-氨基嘧啶衍生物和它们作为腺苷a2a 受体拮抗剂
CN114105887B (zh) 一种氨基嘧啶衍生物及其制备方法和用途
CN101479277A (zh) 作为pi3k抑制剂的嘧啶衍生物
AU2011307220A1 (en) Phenylquinazoline derivatives
HK1092723B (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
AU2002217269A1 (en) Carbazole derivatives and their use as neuropeptide Y5 receptor ligands

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131015